Drug Database
AL

albumin (Pedialb / AlbuRel / AlbuRel LS)

✓ Approved

Reliance Life Sciences Private Limited · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Reliance Life Sciences Private Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesPedialb, AlbuRel, AlbuRel LS
CompanyReliance Life Sciences Private Limited
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Reliance Life Sciences Private Limited

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians2026-07-17

Association of LDH-derived biochemical ratios with severe pre-eclampsia: a multicenter retrospective cohort study.

Geyik Bayman Melike M, Türen Demir Emine E, Kılıç Orhan O, Metin Ülfet Sena ÜS et al.

Pre-eclampsia (PE) is a major pregnancy-related hypertensive disorder associated with increased maternal and perinatal morbidity, particularly in severe cases. Early identification of patients at risk for severe disease remains clinically important, especially using simple and widely accessible laboratory markers. This study aimed to evaluate the association between Lactate dehydrogenase (LDH) derived biochemical ratios and severe pre-eclampsia in a multicenter obstetric cohort. This multicenter retrospective cohort study included 326 pregnant women diagnosed with pre-eclampsia between January 2020 and July 2024 at two tertiary referral centers in Türkiye. Patients were classified as having non-severe pre-eclampsia (n = 116) or severe pre-eclampsia (n = 210) according to established clinical criteria. LDH-derived biochemical ratios, including LDH/albumin, LDH/creatinine, LDH/uric acid, and uric acid/creatinine, were calculated using routinely obtained laboratory parameters. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive performance of these biomarkers for severe disease, while multivariate logistic regression analysis was used to determine independent predictors associated with severe pre-eclampsia. LDH/albumin, LDH/creatinine, and LDH/uric acid ratios were significantly higher in women with severe pre-eclampsia compared with those with non-severe disease (all p < 0.05). Among the evaluated biomarkers, the LDH/albumin ratio demonstrated the best predictive performance for severe pre-eclampsia, with an Area under the curve (AUC) of 0.639 (95% Confidence interval (CI) 0.579-0.702, p < 0.001). An LDH/albumin cutoff value of 11.38 yielded a sensitivity of 36.8% and a specificity of 86.2%. In multivariate logistic regression analysis, the LDH/albumin ratio remained independently associated with severe pre-eclampsia (Odds ratio (OR): 1.19, 95% CI: 1.08-1.31, p < 0.001). LDH-derived biochemical ratios, particularly the LDH/albumin ratio, may represent simple and readily available biomarkers for identifying patients at increased risk for severe pre-eclampsia. Because these parameters are inexpensive and routinely obtained in obstetric practice, they may provide additional support for early risk stratification and clinical assessment. Further prospective multicenter studies are needed to validate these findings.

PMID 42463416
Read full article →
PubMedBMC geriatrics2026-07-17

Predictive value of perioperative D-dimer to albumin ratio for postoperative serious medical complications and one-year mortality in elderly patients with hip fracture: a retrospective study.

Liu Yang Y, Wang Chao C, Xiang Ruyi R, Wang Qi Q et al.

Elderly patients carry high risks of postoperative serious medical complications (PSMC) and mortality, but reliable perioperative predictive indicators remain limited. To evaluate the predictive value of perioperative hematological markers for PSMC and 1-year mortality in elderly surgical patients. A total of 590 patients aged 65-85 years were enrolled. Perioperative blood parameters were measured preoperatively and on postoperative days 1, 3, 5, 7. Patients were grouped by PSMC occurrence and 1-year survival status. ROC analysis was used to assess diagnostic performance. PSMC occurred in 58 patients (9.8%), and 89 patients (15.08%) died within 1 year. Perioperative red blood cells, hemoglobin, albumin, creatinine, procalcitonin, troponin, D-dimer, and D-dimer to albumin ratio (DAR) showed significant dynamic changes (all p < 0.01). The PSMC group had lower albumin and higher D-dimer and DAR than the non-PSMC group (all p < 0.01), with markedly higher 1-year mortality (86.21% vs. 7.33%, p < 0.001). Preoperative DAR showed the comparable predictive power for PSMC (AUC = 0.82), followed by D-dimer (AUC = 0.80) and albumin (AUC = 0.69). For 1-year mortality, D-dimer and DAR both had an AUC of 0.74, with DAR exhibiting higher sensitivity (85.39%). Elevated DAR was significantly associated with increased PSMC and mortality risks (both p < 0.001). Multivariate logistic regression showed high DAR was an independent risk factor for PSMC (OR = 26.82, p < 0.001) and 1-year mortality (OR = 21.75, p < 0.001). Perioperative DAR is a promising prognostic biomarker for PSMC and 1-year mortality in elderly surgical patients. High DAR indicates poor prognosis and may help identify high-risk individuals for targeted intervention.

PMID 42464158
Read full article →
PubMedBMC cardiovascular disorders2026-07-17

Prognostic value of the neutrophil percentage-to-albumin ratio for mortality in patients with hyperuricemia and gout.

Xu Xia-Ying XY, Li Da-Hai DH, Ou Qing Q, Li Yu-Cheng YC et al.

The neutrophil percentage-to-albumin ratio (NPAR) is a composite biomarker reflecting systemic inflammation and nutritional imbalance. Its prognostic significance for mortality in patients with hyperuricemia (HUA) or gout remains incompletely understood, and whether this association differs between asymptomatic HUA and gout has not been examined. We utilized data from the National Health and Nutrition Examination Survey (NHANES, 1999-2018). After applying exclusion criteria, 4,344 adults were identified, comprising 3,659 with asymptomatic hyperuricemia and 685 with gout (56.8% male; median age 52 years). The neutrophil percentage-to-albumin ratio (NPAR) was calculated for each participant. All analyses were stratified by clinical subgroup (asymptomatic hyperuricemia vs. gout). Associations between NPAR and all-cause and cardiovascular mortality were evaluated using Kaplan-Meier analysis, weighted multivariable Cox proportional hazards regression, and restricted cubic spline (RCS) models. To account for competing risks from non-cardiovascular death, Fine-Gray subdistribution hazard models were fitted, and cumulative incidence functions were estimated by the Aalen-Johansen method. In the asymptomatic HUA subgroup, participants in the highest NPAR quartile (Q4) exhibited significantly elevated risks of all-cause mortality (adjusted HR = 2.08, 95% CI: 1.56-2.78, P < 0.001) and cardiovascular mortality (adjusted HR = 2.24, 95% CI: 1.41-3.56, P = 0.001) after full adjustment, compared with the lowest quartile (Q1). In the gout subgroup, the corresponding HR was 2.14 (P = 0.028) for all-cause mortality; for cardiovascular mortality, the quartile-based HR was 3.51 (P = 0.060), while RCS analysis showed a peak HR of 4.95 at the highest NPAR values. NPAR demonstrated strong predictive accuracy in the full cohort, with an AUC of 0.875 for both all-cause and cardiovascular mortality (Model 4, 10-year). In the competing risks analysis, the association between NPAR and cardiovascular mortality remained significant after accounting for non-cardiovascular death as a competing event, with Q4 maintaining an elevated risk across all adjustment levels (fully adjusted sHR = 1.899, 95% CI: 1.366-2.640, P < 0.001; P for trend < 0.001). NPAR is a robust independent predictor of all-cause and cardiovascular mortality in patients with asymptomatic HUA. The association was attenuated in the gout subgroup, likely due to the smaller sample size and limited cardiovascular events, likely reflecting the smaller sample size and limited cardiovascular events. NPAR may serve as a practical clinical biomarker for risk stratification in HUA and gout populations.

PMID 42464146
Read full article →
PubMedEuropean journal of gastroenterology & hepatology2026-07-17

Development of a machine learning-based noninvasive diagnostic model for liver fibrosis in metabolic-associated steatotic liver disease.

Hui Yixin Y, Zeng Yuping Y, Zhang Mei M

To address the lack of simple tools for assessing fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), this study develops a machine learning-based diagnostic model to identify patients at high risk of significant fibrosis and advanced fibrosis. Data from biopsy-proven MASLD patients were randomly divided into training and validation sets. Variables were then selected, and models using Logistic, Support Vector Machine, and eXtreme Gradient Boosting (XGBoost) were compared with identify the optimal model. Finally, Shapley Additive Explanations-based interpretability analysis was applied to explain the best-performing model. The DeLong test was applied to compare the new model with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 index (FIB-4) models. The XGBoost models demonstrated robust accuracy. For the significant fibrosis outcome, the model incorporating age, total cholesterol, glycosylated hemoglobin (HbA1c), and albumin/globulin ratio achieved an area under the receiver operating characteristic curve (AUC) of 0.74 in the training set and 0.72 in the testing set. Regarding the advanced fibrosis outcome, the model including age, total cholesterol, HbA1c, platelets, white cell count, and albumin/globulin ratio yielded an AUC of 0.78 in the training set and 0.74 in the testing set. Decision curve analysis curves confirmed clinical utility, and performance surpassed APRI and FIB-4 (P < 0.05). This study developed a novel noninvasive diagnostic model for MASLD using simple and easily accessible variables, which demonstrates superior performance compared with traditional serological models.

PMID 42464973
Read full article →
PubMedResearch in veterinary science2026-07-17

Thymidine kinase 1 and lactate dehydrogenase activities in plasma and pleural effusion as biomarkers of feline mediastinal lymphoma: Clinical, viral and molecular correlates.

Mon Hla Hsu H, Sirivisoot Sintra S, Vernau William W, Siripoonsub Jedsada J et al.

Feline mediastinal lymphoma is an aggressive cancer needing non-invasive methods for monitoring. This study aims to examine the correlation of thymidine kinase (TK1) and lactate dehydrogenase (LDH) levels in plasma and pleural effusion in cats diagnosed with mediastinal lymphoma and to explore how these markers relate to clinical, pathological, and genetic factors. We analyzed plasma and effusion samples from 30 cats with confirmed mediastinal lymphoma. TK1 was measured using an ELISA assay, and LDH activity and albumin levels were measured using an automatic chemical analyzer. We assessed FeLV infection, cytological grade, immunophenotype, and specific single nucleotide variants (SNVs) in KIT, BCL2, and ZEB1. Lymphoma cats had significantly higher TK1 levels than non-neoplastic controls. A positive correlation was observed between plasma and effusion TK1 levels. No correlation with LDH activity was observed. FeLV-positive cats showed higher plasma TK1 levels and a greater likelihood of elevated effusion. However, fluid TK1 levels were also higher in cats with T-cell lymphomas and those with the ZEB1 c. T > C variant; these differences were not statistically significant. No notable differences were found for LDH or the LDH-to-albumin ratio. The strong correlation and moderate agreement between plasma and pleural effusion TK1 levels potentially indicate that either sample type can be used to assess tumour activity. In contrast, the LDH values differed between the two compartments. Biological factors, including FeLV infection, T-cell phenotype, and ZEB1 variants, may impact tumour activity. This study highlights plasma TK1 as a valuable, non-invasive biomarker for monitoring feline mediastinal lymphoma. However, validation in larger cohorts is needed before clinical application.

PMID 42462498
Read full article →
PubMedmedRxiv : the preprint server for health sciences2026-07-17

Wearable Electrical Impedance Myography for Continuous, Non-Invasive Detection of Acute Compartment Syndrome: A Preclinical Feasibility Study.

Shariyate Mohammad Javad MJ, Khak Mohammad M, Sonbas-Cobb Buket B, Velasquez Hammerle Maria V MV et al.

Acute compartment syndrome (ACS) is a limb-threatening complication of extremity trauma that requires timely diagnosis to prevent irreversible muscle and nerve injury. Current diagnostic methods are invasive, intermittent, and operator-dependent. We evaluated the feasibility of a novel, Bluetooth-enabled electrical impedance myography (EIM) device (mAlert, Myolex, Inc., Brookline, MA, USA) for continuous, noninvasive detection of ACS-related tissue changes. Ten Yorkshire swine underwent anterior tibial compartment monitoring using three ACS models: albumin infusion (ALB, n=3), femoral artery and vein ligation (LIG, n=3), and combined albumin infusion plus ligation (ALB+LIG, n=4). Resistance (R), reactance (X), and phase (P) were measured every minute across 1 to 199 kHz alongside continuous intra-compartmental pressure (ICP) monitoring. Group differences in normalized impedance trends were evaluated using the Kruskal Wallis test with Dunn post hoc correction. As a proof-of-concept human study, nine healthy volunteers wore the device for up to five days to assess electrode durability and signal stability. Tissue ischemia was validated using pimonidazole immunohistochemistry. ALB infusion produced progressive, frequency-dependent decreases in R, X, and P, whereas LIG produced consistent increases in R and X across frequencies. The ALB+LIG model generated mixed responses, reflecting the competing effects of edema and ischemia. Normalized phase slopes differed significantly among groups (H=6.14, p=0.046), with post hoc testing showing significant divergence between the ALB and LIG models (p=0.041). Control limbs remained stable throughout monitoring. Pimonidazole staining confirmed hypoxic injury in the intervention limb. In the human pilot study, three participants completed five days of monitoring, demonstrating sustained signal acquisition, while electrode degradation limited data collection in the remaining participants. This preliminary feasibility study demonstrates that wearable EIM can continuously detect model-specific physiological changes associated with ACS in a large-animal model. These findings support further development and clinical evaluation of wearable EIM as a non-invasive monitoring technology for early ACS detection in trauma patients.

PMID 42465943
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin